Zymeworks’ Ziihera Sets New Survival Benchmark in First-Line HER2-Positive Gastric Cancer Trial
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Zymeworks ( (ZYME) ).
Zymeworks reported positive Phase 3 results from the HERIZON-GEA-01 trial of its engineered HER2-targeted antibody Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without PD-1 inhibitor tislelizumab, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. Both Ziihera-based regimens delivered statistically significant and clinically meaningful improvements in progression-free survival versus the current standard trastuzumab plus chemotherapy, and produced median overall survival of more than two years, including the longest overall survival reported in a Phase 3 GEA trial to date, with benefits consistent across major patient subgroups. The data position Ziihera as a potential new standard of care and HER2 agent-of-choice in first-line metastatic GEA, strengthen Zymeworks’ technology platform and partnership strategy, and could unlock up to $440 million in regulatory milestone payments tied to future approvals in major global markets.
The most recent analyst rating on (ZYME) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and negative operating cash flow) and limited valuation support (negative P/E). These are partially offset by strong technical momentum, a generally upbeat earnings call with narrowing losses and promising clinical data, and favorable corporate developments including positive Phase 3 results and increased share repurchase authorization.
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc., based in Vancouver, is a biotechnology company that manages a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics. Its core focus includes engineering differentiated biologic therapies using its proprietary Azymetric technology platform, with an emphasis on HER2-targeted treatments and partnerships with global pharma players such as Jazz and BeOne to commercialize innovative oncology drugs worldwide.
Average Trading Volume: 1,145,293
Technical Sentiment Signal: Buy
Current Market Cap: $1.92B
Find detailed analytics on ZYME stock on TipRanks’ Stock Analysis page.
